TG Therapeutics, Inc. · TGTX · Next earnings
TG Therapeutics, Inc. reports Thursday, Feb 25, 2027
TGTX reports before market open with consensus EPS at $0.52 and revenue at $290.2M. Last quarter: TG Therapeutics raises 2026 revenue outlook as BRIUMVI momentum continues
What the street expects
Consensus for the coming reportWhere TGTX left off: FY2026 Q3
Full reportTG Therapeutics raises 2026 revenue outlook as BRIUMVI momentum continues
Raised: global full-year revenue guidance is now $1 billion, and U.S. BRIUMVI net revenue guidance is $915–$920 million. The prior-quarter analysis recorded global guidance of approximately $950 million and U.S. guidance of $890–$905 million.
What to watch on the call
Carried forward from the last transcriptAsk FN2 about TGTX next report
Choose a question to continue your researchFree to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Get the TGTX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Recent TGTX quarters
All TGTX earningsSources
- FN2 corporate events calendar, resolved from the earnings calendar feed
- FN2 earnings calendar analyst consensus
- Earnings call transcript analysis, FY2026 Q3
Methodology
The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.
Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.